IDLDX.ST

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Medical - Diagnostics & Research

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$80M	+20.9%	$-0.10	$-0.10–$-0.10	—	1
2027	$105M	+30.0%	$0.00	$0.00–$0.00	—	0
2028	$138M	+32.1%	$0.00	$0.00–$0.00	—	0

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
IDLDX.STIDL Diagnostics AB (publ)	$0.39	-3.25%	$89M	—
ACTI.STActive Biotech AB	$4.21	+2.80%	$111M	—
ATORX.STAlligator Bioscience AB (publ)	$0.02	+1.72%	$1M	—
HEART.STScandinavian Real Heart AB (Publ)	$17.80	+0.56%	$151M	—
ICO.STIconovo AB (publ)	$1.25	+0.00%	$65M	—
IMMNOV.STImmunovia AB	$0.15	-1.58%	$51M	—
LXB.STLuxbright AB (publ)	$0.05	-7.87%	$7M	—

Source: Financial Modeling Prep · peers by sector/industry

IDL Diagnostics AB (publ)

Specializing in in vitro diagnostics (IVD), IDL Diagnostics AB (publ) develops and markets diagnostic tests aimed at detecting cancer and bacterial infections within the Swedish market. Its product portfolio includes UBC Rapid, a point-of-care solution for both diagnosing and tracking bladder cancer; AroCell TK 210 ELISA, utilized as a biomarker for identifying tumor cells; and TUBEX TF, an in vitro diagnostic tool for pinpointing acute typhoid fever. Formerly operating as AroCell AB (publ), the company is scheduled to adopt the name IDL Diagnostics AB (publ) in May 2025. Established in 2000, its operations are headquartered in Stockholm, Sweden.

idldiagnostics.com

Employees: 25
IPO / List date: May 19, 2025
HQ: SE

Held by traders on TradeandTell

No one on the platform currently holds IDLDX.ST.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in IDLDX.ST as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded IDLDX.ST yet.